The effects of Tranquival tablet on some heroin withdrawal symptoms
DOI:
https://doi.org/10.22122/cdj.v3i2.139Keywords:
Clonazepam, Heroin Dependence, Substance Withdrawal SyndromeAbstract
BACKGROUND: Individuals, during opioid withdrawal period, experience symptoms such as dysphoria, insomnia, anxiety, irritability, nausea, agitation, tachycardia, and hypertension which may trigger drug seeking behavior and relapse. This study was conducted with the aim of determining the effect of Tranquival tablets on some heroin withdrawal symptoms in addicted patients referred to an outpatient clinic.
METHODS: In this single-blind quasi-experimental study, 69 patients (37 patients in intervention group and 32 in control group) suffering from heroin withdrawal syndrome were allocated randomly to study groups. In the intervention group, 1 Tranquival tablet was administered 1 hour before sleeping each night for 6 weeks. In the control group, 1 tablet of clonazepam (1 mg) was administered at the same time. The Pittsburgh Sleep Quality Index (PSQI), Hamilton Anxiety Rating Scale (HAM-A), and visual analogue scale (VAS) were completed at the beginning, 3 weeks later, and the end of the study. Data were analyzed using Student’s t-test, repeated measures analysis, and chi-square test.
RESULTS: During the study period in both groups, withdrawal symptoms significantly decreased (P < 0.001); however, this difference was insignificant between the 3 assessment steps (P > 0.050). Furthermore, the Bonferroni correction showed an relationship between Tranquival and clonazepam groups in terms of mean anxiety at the begining and the end stage of assessment (P = 0.012). However, these relationships were insignificant in terms of mean sleep and muscular pain (P = 0.153 and P = 0.267, respectively).
CONCLUSION: Tranquival was as effective as clonazepam in the reduction of muscular pain and anxiety, and improvement of sleep quality in patients suffering from heroin withdrawal syndrome.
References
Sun HM, Li XY, Chow EP, Li T, Xian Y, Lu YH, et al. Methadone maintenance treatment programme reduces criminal activity and improves social well-being of drug users in China: a systematic review and meta-analysis. BMJ Open 2015; 5(1): e005997.
Reingardiene D, Jodziuniene L, Lazauskas R. Methadone treatment and its dangers. Medicina (Kaunas) 2009; 45(5): 419-25.
Gossop M, Bradley B, Phillips GT. An investigation of withdrawal symptoms shown by opiate addicts during and subsequent to a 21-day in-patient methadone detoxification procedure. Addict Behav 1987; 12(1): 1-6.
Swift RM, Stout RL. The relationship between craving, anxiety, and other symptoms in opioid withdrawal. J Subst Abuse 1992; 4(1): 19-26.
Lintzeris N, Nielsen S. Benzodiazepines, methadone and buprenorphine: interactions and clinical management. Am J Addict 2010; 19(1): 59-72.
Bleich A, Gelkopf M, Weizman T, Adelson M. Benzodiazepine abuse in a methadone maintenance treatment clinic in Israel: characteristics and a pharmacotherapeutic approach. Isr J Psychiatry Relat Sci 2002; 39(2): 104-12.
Northrup TF, Stotts AL, Green C, Potter JS, Marino EN, Walker R, et al. Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: a discrete survival and growth mixture model. Addict Behav 2015; 41: 20-8.
Busto U, Sellers EM. Pharmacologic aspects of benzodiazepine tolerance and dependence. J Subst Abuse Treat 1991; 8(1-2): 29-33.
Kavan MG, Elsasser G, Barone EJ. Generalized anxiety disorder: practical assessment and management. Am Fam Physician 2009; 79(9): 785-91.
Head KA, Kelly GS. Nutrients and botanicals for treatment of stress: adrenal fatigue, neurotransmitter imbalance, anxiety, and restless sleep. Altern Med Rev 2009; 14(2): 114-40.
Blumenthal M, Busse WR, Goldberg A. The complete German commission e monographs: therapeutic guide to herbal medicines. Philadelphia, PA: Elsevier Health Sciences; 1999.
Appel K, Rose T, Fiebich B, Kammler T, Hoffmann C, Weiss G. Modulation of the gamma-aminobutyric acid (GABA) system by Passiflora incarnata L. Phytother Res 2011; 25(6): 838-43.
Akhondzadeh S, Kashani L, Mobaseri M, Hosseini SH, Nikzad S, Khani M. Passionflower in the treatment of opiates withdrawal: a double-blind randomized controlled trial. J Clin Pharm Ther 2001; 26(5): 369-73.
Akhondzadeh S, Naghavi HR, Vazirian M, Shayeganpour A, Rashidi H, Khani M. Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. J Clin Pharm Ther 2001; 26(5): 363-7.
Ngan A, Conduit R. A double-blind, placebo-controlled investigation of the effects of Passiflora incarnata (passionflower) herbal tea on subjective sleep quality. Phytother Res 2011; 25(8): 1153-9.
Cronin JR. Passionflower: Reigniting Male Libido and Other Potential Uses. Alternative & Complementary Therapies 2003; 9(2): 89-92.
Herrera-Arellano A, Luna-Villegas G, Cuevas-Uriostegui ML, Alvarez L, Vargas-Pineda G, Zamilpa-Alvarez A, et al. Polysomnographic evaluation of the hypnotic effect of Valeriana edulis standardized extract in patients suffering from insomnia. Planta Med 2001; 67(8): 695-9.
Murphy K, Kubin ZJ, Shepherd JN, Ettinger RH. Valeriana officinalis root extracts have potent anxiolytic effects in laboratory rats. Phytomedicine 2010; 17(8-9): 674-8.
Hattesohl M, Feistel B, Sievers H, Lehnfeld R, Hegger M, Winterhoff H. Extracts of Valeriana officinalis L. s.l. show anxiolytic and antidepressant effects but neither sedative nor myorelaxant properties. Phytomedicine 2008; 15(1-2): 2-15.
Hancianu M, Aprotosoaie AC, Gille E, Poiata A, Tuchilus C, Spac A, et al. Chemical composition and in vitro antimicrobial activity of essential oil of Melissa officinalis L. from Romania. Rev Med Chir Soc Med Nat Iasi 2008; 112(3): 843-7.
Cases J, Ibarra A, Feuillere N, Roller M, Sukkar SG. Pilot trial of Melissa officinalis L. leaf extract in the treatment of volunteers suffering from mild-to-moderate anxiety disorders and sleep disturbances. Med J Nutrition Metab 2011; 4(3): 211-8.
Zanoli P, Zavatti M. Pharmacognostic and pharmacological profile of Humulus lupulus L. J Ethnopharmacol 2008; 116(3): 383-96.
Carpenter JS, Andrykowski MA. Psychometric evaluation of the Pittsburgh Sleep Quality Index. J Psychosom Res 1998; 45(1): 5-13.
Farrahi MJ, Nakhaee N, Sheibani V, Garrusi B, Amirkafi A. Reliability and validity of the Persian version of the Pittsburgh Sleep Quality Index (PSQI-P). Sleep Breath 2012; 16(1): 79-82.
Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32(1): 50-5.
Divsalar P, Shafiei Darbasiabi F, Nasehzadeh A, Divsalar K, Dehyadegary E. The Global Assessment function comparison in bipolar patients at mania episode and mixed episode and analysing the relationship between the anxiety and depression rate of these two groups of patients. Life Science Journal 2013; 10(12s): 1-7.
Boonstra AM, Schiphorst Preuper HR, Reneman MF, Posthumus JB, Stewart RE. Reliability and validity of the visual analogue scale for disability in patients with chronic musculoskeletal pain. Int J Rehabil Res 2008; 31(2): 165-9.
Reddy S, Patt RB. The benzodiazepines as adjuvant analgesics. J Pain Symptom Manage 1994; 9(8): 510-4.
Awad R, Levac D, Cybulska P, Merali Z, Trudeau VL, Arnasona JT. Effects of traditionally used anxiolytic botanicals on enzymes of the ?-aminobutyric acid (GABA) system. Canadian Journal of Physiology and Pharmacology 2007; 85(9): 933-42.
Awad R, Muhammad A, Durst T, Trudeau VL, Arnason JT. Bioassay-guided fractionation of lemon balm (Melissa officinalis L.) using an in vitro measure of GABA transaminase activity. Phytother Res 2009; 23(8): 1075-81.
Miroddi M, Calapai G, Navarra M, Minciullo PL, Gangemi S. Passiflora incarnata L.: ethnopharmacology, clinical application, safety and evaluation of clinical trials. J Ethnopharmacol 2013; 150(3): 791-804.
Andreatini R, Sartori VA, Seabra ML, Leite JR. Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytother Res 2002; 16(7): 650-4.
Guginski G, Luiz AP, Silva MD, Massaro M, Martins DF, Chaves J, et al. Mechanisms involved in the antinociception caused by ethanolic extract obtained from the leaves of Melissa officinalis (lemon balm) in mice. Pharmacol Biochem Behav 2009; 93(1): 10-6.
Zanoli P, Rivasi M, Zavatti M, Brusiani F, Baraldi M. New insight in the neuropharmacological activity of Humulus lupulus L. J Ethnopharmacol 2005; 102(1): 102-6.
Park SH, Sim YB, Kang YJ, Kim SS, Kim CH, Kim SJ, et al. Hop extract produces antinociception by acting on opioid system in mice. Korean J Physiol Pharmacol 2012; 16(3): 187-92.
Kennedy DO, Little W, Haskell CF, Scholey AB. Anxiolytic effects of a combination of Melissa officinalis and Valeriana officinalis during laboratory induced stress. Phytother Res 2006; 20(2): 96-102.
Wahling C, Wegener T, Tschaikin M. Herbal triple combination: An effective alternative to benzodiazepines. Zeitschrift für Phytotherapie 2009; 30(2): 69-72.
